• Report Adverse Event or Product Quality Complaint
  • US Site
  • Global Site
AstraZeneca Medical Information
  • Therapy Areas
    • All Therapeutic Areas
    • Cardiovascular
    • Immunology
    • Infection
    • Metabolic
    • Oncology
    • Renal
    • Respiratory
    • Rare Disease (Alexion)
  • Medications
  • Resources
    • Congress Library
    • Disease Education
    • Pipeline
    • Clinical Trials
    • Open innovation
    • Access 360
    • Affordability Programs
    • Sample Closet
    • Medical Education Grant
    • Rare Disease (Alexion)
  • Connect
    • Connect with Us
    • Find an MSL
    • Request an MSL
    • Submit an MIR
    • Give Feedback
User
  • Login to My AZmedical
  • Register for My AZmedical

Search Medical Information

European Alliance Of Associations For Rheumatology (EULAR) 2024

June 12 - 15, 2024

  1. SAPHNELO (anifrolumab)
  2. Benralizumab
  3. EGPA
  4. Lupus
  5. Lupus Nephritis

html

Anifrolumab for Patients With Moderate to Severe Systemic Lupus Erythematosus: Interim Analysis of a Retrospective Cohort Study

pdf

Glucocorticoid Reduction and Withdrawal in Patients With Systemic Lupus Erythematosus Receiving Long-term Anifrolumab Treatment

pdf

Improvement of Hematological Parameters During Long-term Anifrolumab Treatment and Association With Week 52 BICLA Response

pdf

Lupus Low Disease Activity State Attainment and Reduced Glucocorticoid Use in Patients With SLE in the TULIP Long-term Extension Trial of Anifrolumab

pdf

Improvements in CD163, a Urinary Biomarker of Intrarenal Inflammation, With Anifrolumab: Results From a Phase 2 Trial in Lupus Nephritis

PDF

Renal Outcomes in Patients treated with Anifrolumab for Systemic Lupus Erythematosus in the US: Findings from Real World Study

pdf

Effect of Benralizumab versus Mepolizumab on Reduction in Oral Glucocorticoid Use in Patients With Eosinophilic Granulomatosis with Polyangiitis

pdf

The Efficacy of Eosinophil-targeting Therapies According to ANCA Status in Patients with Eosinophilic Granulomatosis With Polyangiitis: A Post-hoc Analysis of the Phase 3 MANDARA Study

pdf

How Symptoms and Treatments Impact the Experiences of Patients With Eosinophilic Granulomatosis With Polyangiitis Participating in a Clinical Trial

pdf

Incidence, Prevalence and Mortality of EGPA: A Systematic Review and Meta-analysis

html

Diverse Clinical Manifestations of EGPA: A Systematic Review

html

Measuring the Humanistic Burden of EGPA: A Systematic Review

pdf

A Charter to Improve Care for Lupus

pdf

Type I Interferon Pathway is Upregulated in Glomerular and Tubulointerstitial Kidney Compartments of Patients with Lupus Nephritis and Other Renal Diseases

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Request a field medical follow-up

Welcome to AstraZeneca
Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am a payer or formulary decision-maker
I am neither (take me to AstraZeneca.com)
AstraZeneca Logo
Pharma Logo

This site is intended for healthcare professionals practicing in the US.

©2022 AstraZeneca. All rights reserved.

US-69609

Last Updated 11/22

Contact Us

About Us

AstraZeneca-US.com

Grant Opportunities

Survey Feedback

Your Privacy Choices

Privacy Notice

Legal Notice

Cookie Notice

US Site

Global Site

Report Adverse Event or Product Quality Complaint

Pharma Logo

Privacy NoticeLegal NoticeCookie Notice